Ref | Country/year of publication/study setting | Decolonization regimens/study end point(if mentioned) | Results at study end point | Microbiology culture methods/presence of broth enrichment or not |
---|---|---|---|---|
[7] | US/1994/observational study | Oral vancomycin 125 mg q6h for 10 daysa/follow up for 15 days post treatment | VRE negative in 8 (42%) of 19 patients | Campylobacter agar containing 10 μg/ml of vancomycin (B-D Microbiology Systems, Cockeysville, MD, USA)/no broth enrichment |
[7] | US/1994/observational study | Oral bacitracin 25,000 U (500 mg) q6h for 10 days/follow up for 15 days post treatment | VRE negative in 8 (100%) of 8 patients | Campylobacter agar containing 10 μg/ml of vancomycin (B-D Microbiology Systems, Cockeysville, MD, USA)/no broth enrichment |
[15] | US/1995/observational study | Oral novobiocin (500Â mg q6h plus oral tetracycline 500Â mg q6h (five patients) or intravenous doxycycline 100Â mg q12h (one patient) for a median of 3.5Â days (range, 1 to 6Â days) | VRE negative in only one patient while receiving decolonization therapy | Not mentioned |
[8] | US/1995/observational study | Bacitracin 25,000 U (diluted in 5Â mL of 0.9% normal saline) given orally or by gastrostomy tube twice a day for 10Â days/follow up for 3Â weeks post treatment | VRE negative in 5 (63%) of 8 patients | Not mentioned |
[9] | Canada/1999/prospective observational cohort study in a tertiary care institution | Oral doses of bacitracin solution (75,000 U/15 mL) four times daily and doxycycline 100 mg once daily for 14 days/follow up for 4 months | VRE negative in 15 (100%) of the antibiotic treated vs 8 (33.3%) of the untreated patients (P <0 .001) at the end of treatment; but VRE positive in 9 (60%) of 15 and 15 (62.5%) of 24 in the treated and untreated cohort (p = 0.86) following up for a mean of 127 and 130 days respectively b | M-enterococcal agar with vancomycin (6 mg/mL)/no broth enrichment |
[10] | US/2001/randomized, controlled study | Oral zinc bacitracin (50,000 U) q6h for 10Â days vs placebo/follow up for 3Â weeks post treatment | VRE negative in 2 (33%) of 6 patients in each group after 3Â weeks post treatment | Bile esculin agar plates supplemented with 6Â mg/mL of vancomycin/no broth enrichment |
[14] | US/2001/phase II, double-blinded, randomized, multicenter, placebo-controlled study | Oral ramoplanin: 2 daily doses of 100Â mg or 400Â mg or placebo for 7Â days/follow up on day 0, 7, and 14 post treatment | Day 0: VRE negative in 17 (81%) of 21 and 18 (90%) of 20 patients in the 100-mg and 400-mg ramoplanin groups; Day 7: VRE negative in 6 (29%) of 21 and 7 (41%) of 17 in the 100-mg and 400-mg ramoplanin groups; Day 14: VRE negative in 4 (21%) of 19 and 5 (29%) of 17 patients in the 100-mg and 400-mg ramoplanin groupsc | Bile-esculin azide broth that contained 6Â mg/mL of vancomycin (Hardy Diagnostics)/broth enrichment |
[12] | US/2002/observational study | Oral bacitracin (25,000 U three times daily) and oral gentamicin (80Â mg three times daily) for a mean duration of 16Â days (median, 14Â days; range, 7 to 29Â days)/follow up for 3Â months post treatment | VRE negative in 5 (17.8%) of 28 patients | Not mentioned |
[11] | France/2010/observational study in a geriatric rehabilitation care facility | Oral bacitracin 30,000 U three times daily for 15Â days/follow up for 6Â months | VRE negative in 3 (43%) of 7 patients at the end of therapy and at 6Â months | Not mentioned |
[11] | France/2010/observational study in a geriatric rehabilitation care facility | Bacitracin 30,000 U three times daily plus streptomycin 1Â g once daily orally for 15Â days/follow up for 6Â months | VRE negative in 3 (75%) of 4 patients at the end of therapy and at 6Â months | Not mentioned |